MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-741-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$33.56 million
Profitability
Miscellaneous
Employees165
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable
Myokardia (NASDAQ:MYOK) Frequently Asked Questions
What is Myokardia's stock symbol?
Myokardia trades on the NASDAQ under the ticker symbol "MYOK."
How were Myokardia's earnings last quarter?
Myokardia Inc (NASDAQ:MYOK) released its quarterly earnings data on Monday, November, 11th. The biotechnology company reported ($1.34) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.91) by $0.57. View Myokardia's Earnings History.
When is Myokardia's next earnings date?
What price target have analysts set for MYOK?
10 analysts have issued 1-year price targets for Myokardia's stock. Their forecasts range from $70.00 to $95.00. On average, they expect Myokardia's stock price to reach $80.50 in the next year. This suggests a possible upside of 42.0% from the stock's current price. View Analyst Price Targets for Myokardia.
What is the consensus analysts' recommendation for Myokardia?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myokardia in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myokardia.
What are Wall Street analysts saying about Myokardia stock?
Here are some recent quotes from research analysts about Myokardia stock:
- 1. According to Zacks Investment Research, "MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy, DCM-1, treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased DCM heart, HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients and LUS-1, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart, which are in different clinical trial. MyoKardia, Inc. is headquartered in San Francisco, California. " (8/13/2019)
- 2. Cantor Fitzgerald analysts commented, ": 12-month price target of $90. MYOK reported earnings this evening and an increased cash balance of ~ $630M after raising capital in 1Q19. We think that the company is well-capitalized to take advantage of its research discovery platform. One key update today was that the MAVERICK study (non-obstructive) has completed enrollment. We expect that this study will be an important catalyst for the company in 4Q19; we still think that current share levels do not reflect credit for non-obstructive. We still see additional pipeline catalysts beyond mavacamten in obstructive in 2H 2019 that keep us very positive on shares at the current level." (5/9/2019)
Has Myokardia been receiving favorable news coverage?
Media headlines about MYOK stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myokardia earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Myokardia.
Are investors shorting Myokardia?
Myokardia saw a decrease in short interest in the month of October. As of October 15th, there was short interest totalling 4,810,000 shares, a decrease of 6.4% from the September 15th total of 5,140,000 shares. Based on an average daily trading volume, of 278,800 shares, the short-interest ratio is presently 17.3 days. Approximately 11.0% of the shares of the stock are short sold. View Myokardia's Current Options Chain.
Who are some of Myokardia's key competitors?
Some companies that are related to Myokardia include GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Beigene (BGNE), Mylan (MYL), Amarin (AMRN), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Catalent (CTLT), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO) and Dr.Reddy's Laboratories (RDY).
What other stocks do shareholders of Myokardia own?
Who are Myokardia's key executives?
Myokardia's management team includes the folowing people:
- Mr. Tassos Anastasios Gianakakos, Pres, CEO & Director (Age 46)
- Dr. Robert S. McDowell, Chief Scientific Officer (Age 61)
- Dr. June Lee, Exec. VP & Chief Devel. Officer (Age 53)
- Dr. Charles J. Homcy, Advisor (Age 71)
- Dr. Eric J. Topol, Advisor (Age 65)
Who are Myokardia's major shareholders?
Myokardia's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.43%), California Public Employees Retirement System (0.18%), Rhumbline Advisers (0.13%), Handelsbanken Fonder AB (0.11%), State of New Jersey Common Pension Fund D (0.10%) and First Trust Advisors LP (0.09%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, June Lee, Kevin P Starr, Marc Semigran, Sanofi and Taylor C Harris. View Institutional Ownership Trends for Myokardia.
Which major investors are selling Myokardia stock?
MYOK stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and SG Americas Securities LLC. Company insiders that have sold Myokardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, June Lee, Sanofi and Taylor C Harris. View Insider Buying and Selling for Myokardia.
Which major investors are buying Myokardia stock?
MYOK stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State of New Jersey Common Pension Fund D, First Trust Advisors LP, Handelsbanken Fonder AB, Nisa Investment Advisors LLC, NJ State Employees Deferred Compensation Plan, Strs Ohio and Rhumbline Advisers. Company insiders that have bought Myokardia stock in the last two years include Anastasios Gianakakos and Sanofi. View Insider Buying and Selling for Myokardia.
How do I buy shares of Myokardia?
Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Myokardia's stock price today?
One share of MYOK stock can currently be purchased for approximately $56.68.
How big of a company is Myokardia?
Myokardia has a market capitalization of $2.62 billion and generates $33.56 million in revenue each year. The biotechnology company earns $-67,700,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Myokardia employs 165 workers across the globe.View Additional Information About Myokardia.
What is Myokardia's official website?
How can I contact Myokardia?
Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]
MarketBeat Community Rating for Myokardia (NASDAQ MYOK)
MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe MYOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
